gdc

Immunotherapy

First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
Is CAR T-Cell Therapy Safe and Effective?
Cancer ResearchClinical TrialsImmunotherapyPediatric Cancer
Claire White discusses the role of the FDA in evaluating new and promising treatments such as CAR T-cell therapy and the complexity of getting approvals.
Telling Patients About CAR T-Cell Therapy
ImmunotherapyLeukemiaLymphomaPersonalized Medicine
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Immunotherapy plus Chemotherapy Extends Survival for Patients with Metastatic Triple-Negative Breast Cancer
Breast CancerImmunotherapyMetastatic Breast Cancer
Triple-negative breast cancer has few treatment options. Promising results from recent clinical trials of immunotherapy combined with chemotherapy in patients with metastatic disease may soon change the way this aggressive cancer is treated. Just after this article was written, the FDA approved this combination for patients with triple-negative breast cancer.
Immunotherapy vs Targeted Therapy
Immunotherapy
Dr Morganna Freeman explains the difference between immunotherapies and targeted therapies in plain language for patients to easily understand.
Understanding Immunotherapy
Immunotherapy
Dr Morganna Freeman breaks down her methods for explaining immunotherapy to her patients.
Is Immunotherapy Appropriate Here?
Immunotherapy
Dr Morganna Freeman on the challenge of deciding when to treat a patient with immunotherapy.
The Evolving Field of Treatment Modalities
Immunotherapy
Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.
Changing the Conversation: Immunotherapy and Long-Term Survival
Immunotherapy
Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.
Page 1 of 4
Results 1 - 10 of 37

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country